Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
LONDON A global coalition set up a year ago to fight epidemics has struck a $25 million deal with two U.S. biotech companies to accelerate work on a vaccine against the brain-damaging Nipah virus that has killed 12 people in India.
LONDON - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck - seems bound to win.
LONDON Roche's new hemophilia drug Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position.
LONDON U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.
LONDON AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.
LONDON GlaxoSmithKline is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend.
LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.
LONDON Britain must make a continued form of membership of the European Medicines Agency (EMA) a priority to protect the pharmaceutical industry and patients after Brexit, MPs said.
LONDON European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan's market-leading EpiPen injection.
LONDON/TOKYO Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. | Video
- Gold: PRECIOUS-Gold dips slightly as Trump says North Korea talks may continue
- Oil Report: UPDATE 3-Oil output could return to Oct'16 level, says Russia's Novak
- British Pound Report: UPDATE 2-Sterling stuck near 2018 low on Brexit uncertainty, stagnant growth
- US Dollar Report: FOREX-Dollar ends week stronger as commodity-linked peers slip